On July 30, the first trading day after the companies disclosed the negative trial results, Elan's stock fell about 42 percent and Wyeth's stock dropped about 12 percent.
Not only does this provide one-stop shopping for scientists, but also provides them with information they might not easily find elsewhere, such as negative trial results.
By failing to disclose the negative trial results, prosecutors said in the complaint, "Forest told prescribing physicians a half-truth and thereby prevented them and the public from having all potentially available information when making decisions about how to treat a serious medical condition in pediatric patients".
A negative trial will reassure clinicians and blood bankers regarding the effectiveness and safety of standard-issue RBCs.
Although a negative trial can improve patient care by the avoidance of an unnecessary treatment, most trials are designed with the intent of the intervention improving outcomes.
You have just seen a negative trial that should change practice, especially given the way that we, in this country, have been prescribing ezetimibe.
Hiukka's recent negative trial of fenofibrate in type 2 diabetics should not have come as a surprise to those experienced in the acquisition and measurement of intima-media thickness (IMT).
In the past two years Genentech, Pharmacia, Pfizer, AstraZeneca and Johnson & Johnson all have reported negative trial results for their drugs for tumors of the breast, colon, prostate, lung and pancreas, respectively.
Moreover, this trial [35] reported a higher standard deviation with regard to duration of antibiotic treatment as well as antibiotic-free days (possibly due to reported higher non-compliance rate), compared to that in the negative trial [38], which weaken its statistic weight in the meta-analysis.
Along with reviewing the use of ketamine after this negative trial, clinicians need to remain aware of the strength and significance of both placebo and nocebo responses in their own practices and the biopsychosocial complexity of why and how patients actually respond to pain management strategies.
Based on a tip about negative trial results for the drug, SAC Capital in July 2008 began selling off its $700 million position in Elan and Wyeth before the data was made public later that month.
